Eisai, Merck in global oncology deal

Eisai Co. Ltd. (Tokyo:4523) and Merck & Co. Inc. (NYSE:MRK) partnered worldwide to jointly develop and commercialize Eisai's cancer drug Lenvima lenvatinib mesylate

Read the full 235 word article

User Sign In